VEA
CLVS

Virtus ETF Advisers’s Clovis Oncology, Inc. CLVS Stock Holding History

Virtus ETF Advisers’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-57,437
Closed -$116K – 495
2022
Q1 		$116K Sell
57,437
-3,399
-6% -$6.68K 0.05% 277
2021
Q4 		$165K Buy
60,836
+24,426
+67% +$90.3K 0.06% 312
2021
Q3 		$162K Sell
36,410
-1,893
-5% -$9.12K 0.07% 323
2021
Q2 		$222K Buy
+38,303
New +$224K 0.09% 270
2020
Q4 		– Sell
-86,459
Closed -$504K – 365
2020
Q3 		$504K Buy
86,459
+7,282
+9% +$43.6K 0.26% 135
2020
Q2 		$534K Buy
79,177
+33,423
+73% +$253K 0.25% 145
2020
Q1 		$291K Sell
45,754
-3,861
-8% -$31K 0.12% 225
2019
Q4 		$517K Sell
49,615
-3,890
-7% -$28.3K 0.08% 202
2019
Q3 		$210K Sell
53,505
-9,004
-14% -$72.8K 0.04% 239
2019
Q2 		$930K Buy
+62,509
New +$1.13M 0.2% 151
2019
Q1 		– Sell
-30,876
Closed -$555K – 282
2018
Q4 		$555K Buy
30,876
+13,775
+81% +$281K 0.09% 66
2018
Q3 		$502K Buy
17,101
+1,171
+7% +$45.3K 0.05% 122
2018
Q2 		$724K Buy
15,930
+1,827
+13% +$88.9K 0.64% 89
2018
Q1 		$745K Sell
14,103
-826
-6% -$48.2K 0.65% 87
2017
Q4 		$1.01M Sell
14,929
-1,420
-9% -$99.3K 1.27% 15
2017
Q3 		$1.35M Hold
16,349
– – 0.18% 42
2017
Q2 		$1.53M Buy
16,349
+8,552
+110% +$523K 0.23% 34
2017
Q1 		$496K Buy
7,797
+743
+11% +$45.2K 0.09% 102
2016
Q4 		$313K Sell
7,054
-10,811
-61% -$381K 0.09% 108
2016
Q3 		$644K Hold
17,865
– – 0.31% 56
2016
Q2 		$245K Buy
17,865
+10,339
+137% +$151K 0.18% 95
2016
Q1 		$144K Sell
7,526
-473
-6% -$10K 0.2% 126
2015
Q4 		$280K Buy
+7,999
New +$516K 0.77% 45

Other funds holding CLVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

Virtus ETF Advisers's CLVS Position: Q2 2022 in Review

Virtus ETF Advisers sold out of Clovis Oncology, Inc. (CLVS) in Q2 2022, closing a stake of 57,437 shares — an estimated $116K sold.

Virtus ETF Advisers first reported a position in CLVS in Q4 2015 and held it in 23 quarters. The position peaked at $1.53M in Q2 2017. 115 funds tracked by Wall St. Rank hold CLVS as of Q2 2022.

  • Virtus ETF Advisers reported no remaining Clovis Oncology, Inc. position as of Q2 2022 after selling out during the quarter.
  • Virtus ETF Advisers sold 57,437 Clovis Oncology, Inc. shares in Q2 2022, an estimated $116K.
  • Virtus ETF Advisers first reported a position in Clovis Oncology, Inc. in Q4 2015 and held it in 23 quarters.
  • Virtus ETF Advisers's Clovis Oncology, Inc. position peaked at $1.53M in Q2 2017.
  • 115 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2022.

Based on Virtus ETF Advisers's 13F filing for Q2 2022, filed 12 Aug 2022.